The contribution of the sympathetic nervous system to the anabolic effect of estrogen on bone.

The contribution of the sympathetic nervous system to the anabolic effect of estrogen on bone. - E2Bone

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON36023

Enrollment

Registered

2011-03-03

Start date

2011-05-23

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

The participants will be randomized to receive hormonal replacement therapy (HRT) (zumenon 1dd 2 mg), HRT and beta-agonist (terbutaline 1dd 5 mg), beta-antagonist (propranolol SR 1dd 80 mg) or no tr

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: female sex last menstrual cycle 12-60 months ago

Exclusion criteria

Exclusion criteria: Contraindications to HRT, beta-agonist or beta-antagonist treatment, such as cardiovascular disease, astma, COPD, renal or hepatic insufficiency Any medication or disease influencing bone turnover Prior VTE or breast cancer Current osteoporosis defined by a DXA Z-score >-2.5

Design outcomes

Primary

Measure	Time frame
The main study parameter is the difference in change of serum concentrations of bone turnover markers (procollagen type I N propeptide (P1NP) and C-terminal crosslinking telopeptides of collagen type I (CTX)) compared in the treatment and control groups(4).	—

Secondary

Measure	Time frame
A secondary parameter is the change in number of circulating stem cells and osteogenic cells(7).	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)